BioSpace News Archive

uMed says its automated recruitment platform drastically saves time for patients and clinicians including GPs and nurses recruiting for clinical studies.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced they have entered into a distribution agreement with SeaSpine® Orthopedics Corporation, a wholly-owned subsidiary of SeaSpine Holdings Corporation, to exclusively distribute the 7D Surgical FLASH™ Navigation platform for pediatric applications.

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that it will host a data update webcast for investors and analysts during the European Society of Medical Oncology (ESMO) Annual Meeting 2021, September 17, 2021 at 1:30 p.m. ET.

Rezolute, Inc. (Nasdaq: RZLT), today announced that it has begun dosing patients in the second cohort of its Phase 2b clinical trial of RZ358 (RIZE).

TScan Therapeutics, Inc. (Nasdaq: TCRX), today announced that Zoran Zdraveski, J.D., Ph.D. has been appointed as Chief Legal Officer.

Yumanity Therapeutics announced the grant to one new employee of a non-statutory stock option for the purchase of up to an aggregate of 30,000 shares of Yumanity’s common stock.

atai Life Sciences (Nasdaq: ATAI) (“atai”), today announced a usability study of Introspect’s digital therapeutic (DTx) app technology in support of standard of care ketamine therapy for patients with treatment resistant depression (TRD) in collaboration with Kadima Neuropsychiatry.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in a Phase 2 clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AL001 in people with amyotrophic lateral sclerosis (ALS) who carry a C9orf72 mutation.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Investment Conference.